Specifically they found that the drug reduced ejection fractions and left ventricular outflow tract gradients in certain of the 101 individuals who participated in their Phase 1 trials.
The next step for the drug is to try to duplicate these findings in Phase 2 trials which will commence later this year.
A recent article in Science Daily discussed findings of geneticists in the Netherlands which revealed the existence of a mutation in the gene alpha-kinase 3 (ALPK3) which, if inherited from both parents, may cause severe cardiomyopathy in children.
Cardiomyopathy U.K. recently featured this story on their website.
See here for study.
HCM Beat 